U.S., May 12 -- ClinicalTrials.gov registry received information related to the study (NCT07578012) titled 'Prevention With Ismigen of RTIs in Kids' on May 05.
Brief Summary: Although the efficacy of PMBL(R) sublingual tablets is evident to most prescribers, the clinical studies available to demonstrate the efficacy of this bacterial lysate in preventing recurrent respiratory tract infections have undeniable methodological biases. To demonstrate the efficacy of PMBL(R) in the pediatric population without questionable bias, a randomized double-blind Placebo-controlled study will be conducted: one arm of children presenting with a risk of recurrent respiratory tract infections will be treated with PMBL(R) for a 3-month period, 10 days per mo...